RBC Capital Maintains Outperform on Pliant Therapeutics, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) and raises the price target from $50 to $54.
March 05, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Pliant Therapeutics and raises the price target from $50 to $54.
The increase in price target by a reputable analyst like Brian Abrahams signals a strong confidence in Pliant Therapeutics' future performance. This positive outlook is likely to influence investor sentiment positively, leading to a potential short-term increase in PLRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100